{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:02Z","timestamp":1794018542443,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park","award":["Z251100004625078"],"award-info":[{"award-number":["Z251100004625078"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV) 16 infection is associated with several human malignancies. Developing therapeutic vaccines holds great potential for patients who do not benefit from standard care. Circular RNA (circRNA) is an emerging next-generation platform for cancer vaccine development owing to its superior stability and convenient manufacturing process. Herein, we report development of a synthetic circRNA encoding fused HPV16 E7\/E6 antigens encapsulated with lipid nanoparticles (LNP) to treat HPV16-related solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The immunogenicity and anti-tumor immune response of the LNP-circRNA vaccine was determined in na\u00efve C57BL\/6 mice and TC-1 tumor-bearing mice, respectively. Changes in immune cells were examined using flow cytometry and immunofluorescence assay. RNA sequencing was used to identify differentially expressed genes and changes in the tumor microenvironment (TME) of tumors treated with LNP-circRNA\n                      <jats:sup>E7E6<\/jats:sup>\n                      and empty LNP. Anti-tumor efficacy was further evaluated in LNP-circRNA\n                      <jats:sup>E7E6<\/jats:sup>\n                      vaccine combined with anti-PD-L1 antibody treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Prime-boost vaccination with LNP-circRNA\n                      <jats:sup>E7E6<\/jats:sup>\n                      induced a large pool of functional antigen-specific cytotoxic T cells in both the peripheral blood and spleen. This immunization led to profound changes in the TME, characterized by the upregulation of immune activation genes, heavy infiltration of immune cells, and polarization toward a proinflammatory state. Consequently, circRNA\n                      <jats:sup>E7E6<\/jats:sup>\n                      immunization could mediate complete tumor regression and prevent tumor growth. Moreover, vaccination sensitized non-inflamed tumors to immune checkpoint blockade therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The present study results demonstrate that LNP-circRNA\n                      <jats:sup>E7E6<\/jats:sup>\n                      vaccine is capable of eliciting robust anti-tumor immunity in the periphery and TME, highlighting the potential for treating HPV16-related cancers and preventing tumor recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03640-7","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:05:08Z","timestamp":1767787508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity"],"prefix":"10.1186","volume":"45","author":[{"given":"Rong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"3640_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cncr.30947","volume":"124","author":"H Razzaghi","year":"2018","unstructured":"Razzaghi H, Saraiya M, Thompson TD, et al. Five-year relative survival for human papillomavirus-associated cancer sites. Cancer. 2018;124:203\u201311.","journal-title":"Cancer"},{"key":"3640_CR2","doi-asserted-by":"publisher","first-page":"e0203403","DOI":"10.1371\/journal.pone.0203403","volume":"13","author":"BA LeConte","year":"2018","unstructured":"LeConte BA, Szaniszlo P, Fennewald SM, et al. Differences in the viral genome between HPV-positive cervical and oropharyngeal cancer. PLoS ONE. 2018;13:e0203403.","journal-title":"PLoS ONE"},{"key":"3640_CR3","doi-asserted-by":"publisher","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","volume":"13","author":"CA Burmeister","year":"2022","unstructured":"Burmeister CA, Khan SF, Sch\u00e4fer G, et al. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res. 2022;13:200238.","journal-title":"Tumour Virus Res"},{"key":"3640_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10989-021-10334-5","volume":"28","author":"Z Sun","year":"2022","unstructured":"Sun Z, Sun X, Chen Z, et al. Head and neck squamous cell carcinoma: risk factors, molecular alterations, immunology and peptide vaccines. Int J Pept Res Ther. 2022;28:19.","journal-title":"Int J Pept Res Ther"},{"key":"3640_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41568-021-00396-4","volume":"21","author":"K Alfaro","year":"2021","unstructured":"Alfaro K, Maza M, Cremer M, et al. Removing global barriers to cervical cancer prevention and moving towards elimination. Nat Rev Cancer. 2021;21:607\u20138.","journal-title":"Nat Rev Cancer"},{"key":"3640_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","volume":"146","author":"DM Harper","year":"2017","unstructured":"Harper DM, DeMars LR. HPV vaccines - a review of the first decade. Gynecol Oncol. 2017;146:196\u2013204.","journal-title":"Gynecol Oncol"},{"key":"3640_CR7","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1586\/erv.09.123","volume":"8","author":"DM Harper","year":"2009","unstructured":"Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8:1663\u201379.","journal-title":"Expert Rev Vaccines"},{"key":"3640_CR8","doi-asserted-by":"publisher","first-page":"805695","DOI":"10.3389\/fimmu.2021.805695","volume":"12","author":"Z Yousefi","year":"2021","unstructured":"Yousefi Z, Aria H, Ghaedrahmati F, et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy. Front Immunol. 2021;12:805695.","journal-title":"Front Immunol"},{"key":"3640_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","volume":"26","author":"K Hoppe-Seyler","year":"2018","unstructured":"Hoppe-Seyler K, Bossler F, Braun JA, et al. The HPV E6\/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26:158\u201368.","journal-title":"Trends Microbiol"},{"key":"3640_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4143\/crt.2005.37.6.319","volume":"37","author":"EK Yim","year":"2005","unstructured":"Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37:319\u201324.","journal-title":"Cancer Res Treat"},{"key":"3640_CR11","doi-asserted-by":"publisher","first-page":"13174","DOI":"10.1128\/JVI.02172-12","volume":"86","author":"EA White","year":"2012","unstructured":"White EA, Kramer RE, Tan MJ, et al. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol. 2012;86:13174\u201386.","journal-title":"J Virol"},{"key":"3640_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/ITT.S273327","volume":"9","author":"C Smalley Rumfield","year":"2020","unstructured":"Smalley Rumfield C, Roller N, Pellom ST, et al. Therapeutic vaccines for HPV-associated malignancies. Immunotargets Ther. 2020;9:167\u2013200.","journal-title":"Immunotargets Ther"},{"key":"3640_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri1260","volume":"4","author":"IH Frazer","year":"2004","unstructured":"Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004;4:46\u201354.","journal-title":"Nat Rev Immunol"},{"key":"3640_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"3640_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11:823\u201336.","journal-title":"Nat Rev Immunol"},{"key":"3640_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/nat.2017.0717","volume":"28","author":"JJ P\u00e9rez-Trujillo","year":"2018","unstructured":"P\u00e9rez-Trujillo JJ, Robles-Rodr\u00edguez OA, Garza-Morales R, et al. Antitumor response by endoplasmic reticulum-targeting DNA vaccine is improved by adding a KDEL retention signal. Nucleic Acid Ther. 2018;28:252\u201361.","journal-title":"Nucleic Acid Ther"},{"key":"3640_CR17","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185:1728-1744.e1716.","journal-title":"Cell"},{"key":"3640_CR18","doi-asserted-by":"publisher","first-page":"16232","DOI":"10.1073\/pnas.192581299","volume":"99","author":"J Li","year":"2002","unstructured":"Li J, Sun Y, Garen A. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc Natl Acad Sci U S A. 2002;99:16232\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3640_CR19","doi-asserted-by":"crossref","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal. 2011;17:10\u20132.","DOI":"10.14806\/ej.17.1.200"},{"key":"3640_CR20","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/nprot.2016.095","volume":"11","author":"M Pertea","year":"2016","unstructured":"Pertea M, Kim D, Pertea GM, et al. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11:1650\u201367.","journal-title":"Nat Protoc"},{"key":"3640_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3640_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139.","journal-title":"Bioinformatics"},{"key":"3640_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/cgt.2012.55","volume":"19","author":"BG Wieking","year":"2012","unstructured":"Wieking BG, Vermeer DW, Spanos WC, et al. A non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012;19:667\u201374.","journal-title":"Cancer Gene Ther"},{"key":"3640_CR24","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1128\/JVI.02188-07","volume":"82","author":"WC Spanos","year":"2008","unstructured":"Spanos WC, Hoover A, Harris GF, et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol. 2008;82:2493\u2013500.","journal-title":"J Virol"},{"key":"3640_CR25","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.4049\/jimmunol.151.11.6175","volume":"151","author":"JC Reece","year":"1993","unstructured":"Reece JC, Geysen HM, Rodda SJ. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol. 1993;151:6175\u201384.","journal-title":"J Immunol"},{"key":"3640_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-4939-7389-7_16","volume":"1691","author":"J Schoberer","year":"2018","unstructured":"Schoberer J, Shin YJ, Vavra U, et al. Analysis of protein glycosylation in the ER. Methods Mol Biol. 2018;1691:205\u201322.","journal-title":"Methods Mol Biol"},{"key":"3640_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12192-018-0952-8","volume":"24","author":"DH Mart\u00ednez-Puente","year":"2019","unstructured":"Mart\u00ednez-Puente DH, P\u00e9rez-Trujillo JJ, Guti\u00e9rrez-Puente Y, et al. Targeting HPV-16 antigens to the endoplasmic reticulum induces an endoplasmic reticulum stress response. Cell Stress Chaperones. 2019;24:149\u201358.","journal-title":"Cell Stress Chaperones"},{"key":"3640_CR28","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.4049\/jimmunol.167.3.1558","volume":"167","author":"J Rice","year":"2001","unstructured":"Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol. 2001;167:1558\u201365.","journal-title":"J Immunol"},{"key":"3640_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.0105-2896.2004.00145.x","volume":"199","author":"FK Stevenson","year":"2004","unstructured":"Stevenson FK, Rice J, Ottensmeier CH, et al. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev. 2004;199:156\u201380.","journal-title":"Immunol Rev"},{"key":"3640_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","volume":"73","author":"C Badoual","year":"2013","unstructured":"Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128\u201338.","journal-title":"Cancer Res"},{"key":"3640_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/cgt.2015.40","volume":"22","author":"AE Rice","year":"2015","unstructured":"Rice AE, Latchman YE, Balint JP, et al. An HPV-E6\/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 2015;22:454\u201362.","journal-title":"Cancer Gene Ther"},{"key":"3640_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-016-0169-2","volume":"4","author":"GM Weir","year":"2016","unstructured":"Weir GM, Hrytsenko O, Quinton T, et al. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer. 2016;4:68.","journal-title":"J Immunother Cancer"},{"key":"3640_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","volume":"5","author":"A Chabeda","year":"2018","unstructured":"Chabeda A, Yanez RJR, Lamprecht R, et al. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018;5:46\u201358.","journal-title":"Papillomavirus Res"},{"key":"3640_CR34","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.ymthe.2024.04.036","volume":"32","author":"J Wang","year":"2024","unstructured":"Wang J, Wang Q, Ma L, et al. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies. Mol Ther. 2024;32:2340\u201356.","journal-title":"Mol Ther"},{"key":"3640_CR35","doi-asserted-by":"publisher","first-page":"1213285","DOI":"10.3389\/fimmu.2023.1213285","volume":"14","author":"K Zhou","year":"2023","unstructured":"Zhou K, Yuzhakov O, Behloul N, et al. HPV16 E6\/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions. Front Immunol. 2023;14:1213285.","journal-title":"Front Immunol"},{"key":"3640_CR36","doi-asserted-by":"publisher","first-page":"e1629259","DOI":"10.1080\/2162402X.2019.1629259","volume":"8","author":"C Grunwitz","year":"2019","unstructured":"Grunwitz C, Salomon N, Vascotto F, et al. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology. 2019;8:e1629259.","journal-title":"Oncoimmunology"},{"key":"3640_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.addr.2005.11.003","volume":"58","author":"SH van der Burg","year":"2006","unstructured":"van der Burg SH, Bijker MS, Welters MJ, et al. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev. 2006;58:916\u201330.","journal-title":"Adv Drug Deliv Rev"},{"key":"3640_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","volume":"471","author":"R Wang","year":"2020","unstructured":"Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88\u2013102.","journal-title":"Cancer Lett"},{"key":"3640_CR39","unstructured":"Inovio. Inovio reports fourth quarter and full year 2022 financial results and clinical highlights. 2022."},{"key":"3640_CR40","doi-asserted-by":"crossref","unstructured":"Hillemanns P, Zikan M, Forget F, et al. Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study. J Immunother Cancer. 2025;13:e010827.","DOI":"10.1136\/jitc-2024-010827"},{"key":"3640_CR41","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.eclinm.2024.102716","volume":"74","author":"MC Lim","year":"2024","unstructured":"Lim MC, Choi YJ, Hur SY, et al. GX-188E DNA vaccine plus pembrolizumab in HPV 16- and\/or 18-positive recurrent or advance cervical cancer: a phase 2 trial. EClinicalMedicine. 2024;74:102716.","journal-title":"EClinicalMedicine"},{"key":"3640_CR42","unstructured":"Biontech. Exploratory analysis of antitumor activity and translational results from the safety run-in of AHEAD-MERIT, a phase 2 trial of first-line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC. 2024."},{"key":"3640_CR43","unstructured":"Biontech. HARE-40: a phase I\/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma. 2024."},{"key":"3640_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries O, Mc Cafferty S, De Smedt SC, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337\u201344.","journal-title":"J Control Release"},{"key":"3640_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","volume":"625","author":"TE Mulroney","year":"2024","unstructured":"Mulroney TE, P\u00f6yry T, Yam-Puc JC, et al. N(1)-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature. 2024;625:189\u201394.","journal-title":"Nature"},{"key":"3640_CR46","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.omtn.2023.102045","volume":"34","author":"Z Wang","year":"2023","unstructured":"Wang Z, Jacobus EJ, Stirling DC, et al. Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice. Mol Ther Nucleic Acids. 2023;34:102045.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3640_CR47","doi-asserted-by":"publisher","first-page":"e2302191120","DOI":"10.1073\/pnas.2302191120","volume":"120","author":"L Amaya","year":"2023","unstructured":"Amaya L, Grigoryan L, Li Z, et al. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci U S A. 2023;120:e2302191120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3640_CR48","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.7150\/thno.77350","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Peng K, Yang K, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12:6422\u201336.","journal-title":"Theranostics"},{"key":"3640_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","volume":"9","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu X, Shen T, et al. Small circular RNAs as vaccines for cancer immunotherapy. Nat Biomed Eng. 2025;9:249\u201367.","journal-title":"Nat Biomed Eng"},{"key":"3640_CR50","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7150\/thno.104698","volume":"15","author":"H Yu","year":"2025","unstructured":"Yu H, Wen Y, Yu W, et al. Optimized circular RNA vaccines for superior cancer immunotherapy. Theranostics. 2025;15:1420\u201338.","journal-title":"Theranostics"},{"key":"3640_CR51","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1016\/j.vaccine.2008.03.069","volume":"26","author":"J Yan","year":"2008","unstructured":"Yan J, Harris K, Khan AS, et al. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6\/E7 fusion consensus protein in mice and rhesus macaques. Vaccine. 2008;26:5210\u20135.","journal-title":"Vaccine"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03640-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:02:51Z","timestamp":1770206571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03640-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3640"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03640-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai Model Organisms Center. Consent to participate declaration: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LG, JZ, RZ, CL, LC, LL are co-inventors on a patent related to a circular RNA-based therapeutic vaccine for treating HPV positive cancer (International application number: PCT\/CN2025\/076310). All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}